Compare TG Therapeutics Inc (TGTX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Williams-Sonoma, Inc. — how do they compare? TG Therapeutics Inc trades at $55.14 (market cap $8.16B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 3.4× TG Therapeutics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Williams-Sonoma, Inc. for 59 Days on average.
| TGTX | WSM | |
|---|---|---|
Market Cap | $8.16B | $28.15B |
Volume | 1,735,121 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $251.81 |
52-Week Low | $26.94 | $168.64 |
Typical Hold Time | 16 Days | 59 Days |
Enterprise Value | $8.37B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Williams-Sonoma (WSM) trades at $241.78, up 0.55% on the day, reflecting strong momentum near its consensus price target of $246.31. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 14.73% net income margin and consistent earnings beats in recent quarters. Recent news highlights market share gains and profitability improvements, with the company raising full-year guidance after strong Q2 2026 results.
The outlook remains positive given WSM's operational efficiency and dividend growth, though risks include housing market sensitivity and competitive pressures. Analyst consensus leans bullish with 32% buy ratings, but high valuation multiples like a P/E of 24.51 warrant caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
